Recent advances in distal myopathy with rimmed vacuoles (DMRV) or hIBM: Treatment perspectives

Current Opinion in Neurology

Volumn 21, Issue 5, 2008, Pages 596-600

  Malicdan, May Christine V ^a   Noguchi, Satoru ^a   Nishino, Ichizo ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NONE   (Japan)

Author keywords

Amyloid; Muscle atrophy; Sialic acid

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; MEMBRANE METALLOENDOPEPTIDASE; NERVE CELL ADHESION MOLECULE; SIALIC ACID;

ALZHEIMER DISEASE; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CELL VACUOLE; CONTINUOUS INFUSION; DISTAL MYOPATHY; GENE MUTATION; HEREDITARY INCLUSION BODY MYOPATHY; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

AMYLOID; ANIMALS; DISTAL MYOPATHIES; GLYCOPROTEINS; HUMANS; MULTIENZYME COMPLEXES; MYOSITIS, INCLUSION BODY; SIALIC ACIDS; VACUOLES;

EID: 53549111872     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32830dd595     Document Type: Review

References (45)

1. Nonaka I, Noguchi S, Nishino I. Distal myopathy with rimmed vacuoles and hereditary inclusion body myopathy. Curr Neural Neurosci Rep 2005; 5:61-65.
2. Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002; 59:1689-1693.
3. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N- acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29:83-87.
4. Kayashima T, Matsuo H, Satoh A, et al. Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE). J Hum Genet 2002; 47:77-79.
5. Keppler T, Hinderlich S, Langner J, et al. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 1999; 284:1372-1376.
6. Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cellcell interactions and signalling. Curr Opinion Struct Biol 2000; 12:609-615.
7. Corfield AP, Schauer R. Occurrence of sialic acids, in: Schauer R, editor. Sialic acids. Chemistry, metabolism, and function. Vols 5-50. Wien, New York: Springer; 1982.
8. Noguchi S, Keira Y, Murayama K, et al. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem 2004; 279:11402-11407.
9. Askanas V, Engel WK. Inclusion body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 2002; 15:525-531.
10. Askanas V, Engel WK. Proposed pathogenic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003; 15:734-744.
11. Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta-APP in skeletal muscle. Proc Nat Acad Sci 2002; 99:6334-6339.
12. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39:409-421.
13. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 2007; 28:1297-1306.
14. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008; 5:212-224. This is a study that describes various strategies that employ the manipulation of amyloid degrading enzymes to effectively lower the amyloid burden.
15. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74:342-352.
16. Tyler SJ, Dawbam D, Wilcock GK, Allen SJ. Alpha- and beta-secretases: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 2003; 299:373-376.
17. Hooper NM. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 2005; 33: 335-338.
18. Kinoshita A, Fukumoto H, Shah T, et al. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 2003; 116:3339-3346.
19. Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 2008; 5:212-214. This is a good review on the role of neprilysin and amyloid.
20. Cam JA, Zerbinatti CV, Knisely JM, et al. The low density lipoprotein receptorrelated protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 2004; 279:29639-29646.
21. Koo EH, Squazzo SL Evidence that production and release of amyloid βprotein involves the endocytic pathway. J Biol Chem 2004; 269:17386-17389.
22. Bu G, Cam J, Zerbinatti C. LRP in amyloid-βproduction and metabolism. Ann N Y Acad Sci 2006; 1086:35-53.
23. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9:907-913.
24. Clifford PM, Zarrabi S, Siu G, et al. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 2007; 1142:223-236.
25. Yazawa H, Yu ZX, Takeda, et al. Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 2001; 15:2454-2462.
26. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8:1051-1058.
27. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003; 350:113-116.
28. El-Amouri SS, Zhu H, Yu J, et al. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007; 1152:191-200.
29. Askanas V, Engel WK. Hereditary inclusion myopathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ, editors. The molecular and genetic basis of neurologic and psychiatric disease, 3rd ed. Woburn, Massachusetts: Butterworth-Heinemann; 2003. pp. 501-509.
30. Broccolini A, Gidaro T, Morosetti R, et al. Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. J Neurochem 2006; 96:777-789.
31. Salama I, Hinderlich S, Shlomai Z, et al. No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation. Biochem Biophys Res Commun 2005; 328:221-226.
32. Hinderlich S, Salama I, Eisenberg I, et al. The homozygous M712Tmutationof UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase results in reduced enzyme activities but not in altered overall cellular sialylation in hereditary inclusion body myopathy. FEBS Lett 2004; 566:105-109.
33. Broccolini A, Gliubizzi C, Pavoni E, et al. Alpha-dystrogrycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy. Neuromuscul Disord 2005; 15:177-184.
34. Huizing M, Rakocevic G, Sparks SE, et al. Hypoglycosylation of alphadystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab 2004; 81:196-202.
35. Saito F, Tomimitsu H, Arai K, et al. A Japanese patient with distal myopathy with rimmed vacuoles: missense mutations in the epimerase domain of the UDP-N-acetylglucosamine 2-epimerase/N-acetyImannosamine kinase (GNE) gene accompanied by hyposialylation of skeletal muscle glycoproteins. Neuromuscul Disord 2004; 14:158-161.
36. Motozaki Y, Komai K, Hirohata M, et al. Hereditary inclusion body myopathy with a novel mutation in the GNE gene associated with proximal leg weakness and necrotizing myopathy. Eur J Neurol 2007; 14:e14-e15.
37. Ricci E, Broccolini A, Gidaro T, et al. NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. Neurology 2006; 66:755-758.
38. Broccolini A, Gidaro T, De Cristofaro R, et al. Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusionbody myopathy muscle. J Neurochem 2008; 105:971-981. This study demonstrates that neprilysin, an amyloid-β cleaving enzyme, is hyposialylated, and this hyposialylation is directty correlated to its decreased enzymatic activity. It may be surmised that hyposiarylation of certain proteins could lead to the increase of amyloid-β burden.
39. Schwarzkopf M, Knobeloch KP, Rohde E, et al. Sialylation is essential for early development in mice. Proc Natl Acad Sci 2002; 99:5267-5270.
40. Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe gtomenJar proteinuria and is rescued by N-acetylmannosamine. J Clin Invest 2007; 117:1585-1594. Despite the fact that the phenotype in these mice is severe and lethal, it underscores the importance of sialic acid in the survival of mice. More importantly, the administration of ManNAc, as already has been shown in previous studies, could increase the GNE enzymatic activities and protein expression in tissues and increase the sialylation of a major kidney glycoprotein.
41. Keriaschki D, Vemillo AT, Farquhar MG. Reduced sialylation of podocalyxinthe major sialoprotein of the rat kidney glomerulus - in aminonucleoside nephrosis. Am J Pathol 1985; 118:343-349.
42. Wang Z, Sun Z, Li AV, Yarema KJ. Roles for UDP-GlcNAc2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation. J Biol Chem 2006; 281:27016-27028.
43. Malicdan MC, Noguchi S, Nonaka I, et al. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum Mol Genet 2007; 16:2669-2682. This study presents the model mouse that replicates the biochemical, clinical, and pathological phenotype of DMRV/hlBM among patients. Furthermore, it highlights the role of hyposialylation in this myopathy caused by GNE mutation and the presence of intracellular amyloid accumulation as an earlier event to rimmed vacuole formation or myolibrillar degeneration.
44. Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60:1-14.
45. Sparks S, Rakocevic G, Joe G, Manoli, et at. Intravenous immune globulin in hereditary inclusion body myopathy a pilot study. BMC Neurol 2007; 7:3. Despite this work being a pilot study, this is the first attempt to treat OMRV/hlBM patients on the basis of the concept of hyposialylation.